Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124912123 | 12491212 | 3 | F | 20160613 | 20160728 | 20160623 | 20160810 | EXP | CA-ALEXION PHARMACEUTICALS INC-A201604535 | ALEXION | 79.82 | YR | M | Y | 96.50000 | KG | 20160810 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124912123 | 12491212 | 1 | PS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 600 MG, QW | AD9022B01 | 125166 | 600 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | /wk | |||||
| 124912123 | 12491212 | 2 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, Q2W | AD9022B01 | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||||
| 124912123 | 12491212 | 3 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, Q2W | AE4703B03 | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||||
| 124912123 | 12491212 | 4 | SS | SOLIRIS | ECULIZUMAB | 1 | Intravenous (not otherwise specified) | 900 MG, Q2W | AE7317B04 | 125166 | 900 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | QOW | |||||
| 124912123 | 12491212 | 5 | C | VITAMIN D /00107901/ | ERGOCALCIFEROL | 1 | Oral | 1000 IU, QD | 0 | 1000 | IU | QD | |||||||
| 124912123 | 12491212 | 6 | C | ASA | ASPIRIN | 1 | Oral | 81 MG, QD | 0 | 81 | MG | QD | |||||||
| 124912123 | 12491212 | 7 | C | AVODART | DUTASTERIDE | 1 | Oral | 0.5 MG, QD | 0 | .5 | MG | QD | |||||||
| 124912123 | 12491212 | 8 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 20 MG, QD | 0 | 20 | MG | QD | |||||||
| 124912123 | 12491212 | 9 | C | DIOVAN | VALSARTAN | 1 | Oral | 80 MG, QD | 0 | 80 | MG | QD | |||||||
| 124912123 | 12491212 | 10 | C | BISOPROLOL | BISOPROLOL | 1 | Oral | 5 MG, QD | 0 | 5 | MG | QD | |||||||
| 124912123 | 12491212 | 11 | C | FOLIC ACID. | FOLIC ACID | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124912123 | 12491212 | 1 | Paroxysmal nocturnal haemoglobinuria |
| 124912123 | 12491212 | 5 | Vitamin supplementation |
| 124912123 | 12491212 | 6 | Anticoagulant therapy |
| 124912123 | 12491212 | 7 | Benign prostatic hyperplasia |
| 124912123 | 12491212 | 8 | Product used for unknown indication |
| 124912123 | 12491212 | 9 | Product used for unknown indication |
| 124912123 | 12491212 | 10 | Product used for unknown indication |
| 124912123 | 12491212 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124912123 | 12491212 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124912123 | 12491212 | Anaemia | |
| 124912123 | 12491212 | Poor venous access |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124912123 | 12491212 | 1 | 20151111 | 20151202 | 0 | |
| 124912123 | 12491212 | 2 | 20151209 | 0 | ||
| 124912123 | 12491212 | 3 | 20151209 | 0 | ||
| 124912123 | 12491212 | 4 | 20151209 | 0 | ||
| 124912123 | 12491212 | 7 | 20140417 | 0 |